Dermapharm Holding SE
DMPGermany
30 filed reports · 166 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
30 reports · Sep 2017 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Half YearBundesanzeiger | 9 | 776 | Jun 2018 to Jun 2026 |
| Q1Bundesanzeiger | 8 | 587 | Mar 2019 to Mar 2026 |
| Q3Bundesanzeiger | 8 | 490 | Sep 2017 to Sep 2025 |
| AnnualBundesanzeiger | 5 | 348 | Dec 2021 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | half year | Jun 30, 2026 | Jun 30, 2026 | 111 | Open |
| FY2026 Q1 | q1 | Mar 31, 2026 | Mar 31, 2026 | 87 | Open |
| FY2025 | annual | Dec 31, 2025 | Dec 31, 2025 | 70 | Open |
| FY2025 Q3 | q3 | Sep 30, 2025 | Sep 30, 2025 | 70 | Open |
| FY2025 Q2 | half year | Jun 30, 2025 | Jun 30, 2025 | 45 | Open |
| FY2025 Q1 | q1 | Mar 31, 2025 | Mar 31, 2025 | 69 | Open |
| FY2024 | annual | Dec 31, 2024 | Dec 31, 2024 | 71 | Open |
| FY2024 Q3 | q3 | Sep 30, 2024 | Sep 30, 2024 | 72 | Open |
| FY2024 Q2 | half year | Jun 30, 2024 | Jun 30, 2024 | 88 | Open |
| FY2024 Q1 | q1 | Mar 31, 2024 | Mar 31, 2024 | 42 | Open |
| FY2023 | annual | Dec 31, 2023 | Dec 31, 2023 | 69 | Open |
| FY2023 Q3 | q3 | Sep 30, 2023 | Sep 30, 2023 | 44 | Open |
Financial data
166 concepts · 2,201 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
IFRS154 concepts · 2,009 facts · Sep 2017 to Jun 2026
- Stockholders Equity44 · Dec 2017 to Jun 2026
- Operating Income32 · Jun 2018 to Jun 2026
- Total Assets31 · Sep 2017 to Jun 2026
- Total Current Assets31 · Dec 2017 to Jun 2026
- Total Current Liabilities31 · Dec 2017 to Jun 2026
- Total non-current assets30 · Dec 2017 to Jun 2026
- Accounts Payable29 · Jun 2018 to Jun 2026
- Accounts Receivable, Net29 · Jun 2018 to Jun 2026
- Cash and Equivalents29 · Sep 2017 to Jun 2026
- Current financial liabilities29 · Dec 2017 to Jun 2026
- Equity investments29 · Jun 2018 to Jun 2026
- Goodwill29 · Jun 2018 to Jun 2026
- Intangible Assets (excluding Goodwill)29 · Jun 2018 to Jun 2026
- Inventory29 · Jun 2018 to Jun 2026
- Investments accounted for using the equity method29 · Jun 2018 to Jun 2026
- Non-current financial liabilities29 · Jun 2018 to Jun 2026
- Other current financial assets29 · Dec 2017 to Jun 2026
- Other provisions29 · Jun 2018 to Jun 2026
- Property, Plant & Equipment, Net29 · Jun 2018 to Jun 2026
- Revenue29 · Jun 2018 to Jun 2026
- Total non-current liabilities29 · Dec 2017 to Jun 2026
- Capital reserves28 · Jun 2018 to Jun 2026
- Deferred tax liabilities28 · Jun 2018 to Jun 2026
- Other current assets28 · Mar 2019 to Jun 2026
Segment9 concepts · 169 facts · Jun 2018 to Jun 2026
- EBITDA margin37 · Jun 2018 to Jun 2026
- EBITDA (unadjusted)28 · Jun 2018 to Jun 2026
- Reported revenue in the “Parallel import business“ segment28 · Jun 2018 to Jun 2026
- Revenue28 · Jun 2018 to Jun 2026
- of which intersegment revenue16 · Mar 2019 to Jun 2026
- of which earnings from investments accounted for using the equity method11 · Mar 2020 to Jun 2026
- Revenue from external customers9 · Mar 2021 to Mar 2022
- Cost of materials6 · Mar 2026 to Jun 2026
- Personnel expenses6 · Mar 2026 to Jun 2026
KPI1 concepts · 15 facts · Mar 2021 to Dec 2025
- Equity ratio15 · Mar 2021 to Dec 2025
APM2 concepts · 8 facts · Jun 2018 to Sep 2020
- EBITDA7 · Jun 2018 to Sep 2020
- non-recurring expenses and provisions1 · Sep 2020
Segments
169 factsFigures broken down by business line, region, product or another axis the company reports on.
Business segment7 members · 169 facts
- Parallel import business50 · Jun 2018 to Jun 2026
- Branded pharmaceuticals and other healthcare products45 · Jun 2018 to Mar 2022
- Herbal extracts37 · Mar 2019 to Mar 2022
- Branded pharmaceuticals15 · Mar 2026 to Jun 2026
- Other healthcare products14 · Mar 2026 to Jun 2026
- Parallel imports4 · Jun 2018
- Pharmaceuticals and other healthcare products4 · Jun 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.